Treating advanced hepatocellular carcinoma: How to get out of first gear.
作者： James J. Harding , Ghassan K. Abou-Alfa
DOI: 10.1002/CNCR.28850
关键词:
摘要: Hepatocellular carcinoma is a common malignancy with poor prognosis. Sorafenib the only systemic therapy known to improve overall survival of patients advanced disease. The clinical benefit sorafenib modest and mechanistic basis for its activity unknown. Four phase 3 trials have failed on in frontline setting no agent has been shown impact outcomes after failure. Several factors contributed this recent stall drug development but new approaches hold promise currently are being investigated. This review will focus current pipeline experimental therapeutics hepatocellular shed light scientific limitations that hamper advancement therapies disease, ways around it.
sci-hub.se 参考文章(77)
Julien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean-Luc Raoul, Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. ,vol. 118, pp. 147- 156 ,(2012) , 10.1002/CNCR.26255
George D. Yancopoulos, Samuel Davis, Nicholas W. Gale, John S. Rudge, Stanley J. Wiegand, Jocelyn Holash, Vascular-specific growth factors and blood vessel formation Nature. ,vol. 407, pp. 242- 248 ,(2000) , 10.1038/35025215
Chad A Wiesenauer, Michele T Yip-Schneider, Yufang Wang, C.Max Schmidt, Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. Journal of The American College of Surgeons. ,vol. 198, pp. 410- 421 ,(2004) , 10.1016/J.JAMCOLLSURG.2003.10.004
Frederick W. Holtsberg, John S. Bomalaski, Charles Mark Ensor, Mike A. Clark, Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Research. ,vol. 62, pp. 5443- 5450 ,(2002)
Alok A. Khorana, Eric S. Kim, David J. Stewart, Can EGFR mutation status evolve with chemotherapy Chinese clinical oncology. ,vol. 2, pp. 1- 1 ,(2013) , 10.3978/J.ISSN.2304-3865.2012.11.09
Alireza S. Alavi, Lisette Acevedo, Wang Min, David A. Cheresh, Chemoresistance of Endothelial Cells Induced by Basic Fibroblast Growth Factor Depends on Raf-1–Mediated Inhibition of the Proapoptotic Kinase, ASK1 Cancer Research. ,vol. 67, pp. 2766- 2772 ,(2007) , 10.1158/0008-5472.CAN-06-3648
Ghassan K. Abou-Alfa, Philip Johnson, Jennifer J. Knox, Marinela Capanu, Irina Davidenko, Juan Lacava, Thomas Leung, Bolorsukh Gansukh, Leonard B. Saltz, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. ,vol. 304, pp. 2154- 2160 ,(2010) , 10.1001/JAMA.2010.1672
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
S Giambartolomei, F Covone, M Levrero, C Balsano, Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein Oncogene. ,vol. 20, pp. 2606- 2610 ,(2001) , 10.1038/SJ.ONC.1204372
Jian Huang, Qing Deng, Qun Wang, Kun-Yu Li, Ji-Hong Dai, Niu Li, Zhi-Dong Zhu, Bo Zhou, Xiao-Yan Liu, Rui-Fang Liu, Qian-Lan Fei, Hui Chen, Bing Cai, Boping Zhou, Hua-Sheng Xiao, Lun-Xiu Qin, Ze-Guang Han, Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma Nature Genetics. ,vol. 44, pp. 1117- 1121 ,(2012) , 10.1038/NG.2391